Friday 6 November 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
146.38
9.74
−6.24%
Follow PODD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 9 | 8 |
| 18.12% | 23.00% | 26.02% | 28.94% | ||
| 7.87% | 9.31% | 11.31% | 13.31% | ||
ROIC |
16.94% | 17.90% | 17.56% | 18.77% | |
Return on Tangible Assets |
12.03% | 16.35% | 19.11% | 19.98% | |
Average Days of Receivables |
69.67 | 68.54 | 70.37 | 78.86 | |
Free Cash Flow per Share |
4.97 | 5.54 | 3.83 | 3.35 | |
Free Cash Flow |
349.90 | 387.80 | 265.60 | 232.60 | |
Capital Expenditures |
(219.40) | (231.50) | (245.60) | (276.40) | |
| Other line items | |||||
Cash ROIC |
11.00% | 14.20% | 9.14% | 7.44% | |
Accounts Receivable Turnover |
6.14 | 6.13 | 5.91 | 5.54 | |
Accounts Payable Turnover |
16.21 | 8.11 | 8.05 | 8.53 | |
Inventory Turnover |
1.74 | 1.86 | 1.90 | 1.80 | |
Average Days of Payables |
35.64 | 65.01 | 50.96 | 66.01 | |
Days of Inventory on Hand |
215.05 | 200.73 | 200.35 | 224.68 | |
Tax Rate |
(0.27) | (0.25) | (0.24) | (0.22) | |
Research and Development Expense of Revenue |
11.12% | 11.42% | 11.33% | 11.30% | |
Selling, General and Administrative Expense of Revenue |
43.02% | 42.11% | 42.86% | 42.15% | |
Share Based Compensation of Revenue |
2.32% | 2.27% | 2.55% | 2.56% | |
Interest Coverage |
7.98 | 7.81 | 8.77 | 9.90 | |
Operating CF/Net income |
2.30 | 2.05 | 1.36 | 1.19 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.12 | 0.11 | |
Capex/Depreciation |
(2.43) | (2.44) | (2.47) | (2.62) | |
Revenue per Share |
38.50 | 41.45 | 44.06 | 45.98 | |
Operating CF per Share |
8.09 | 8.85 | 7.38 | 7.34 | |
Capex per Share |
(3.12) | (3.31) | (3.54) | (3.99) | |
Capex to Sales |
0.08 | 0.08 | 0.08 | 0.09 |
Columns are period end dates · fundamentals updated 6 Nov 2026